TY - JOUR N2 - Atopic dermatitis (AD) is the most frequent allergic disease in dogs. AD can be treated using allergenspecific immunotherapy as well as symptomatic antipruritic treatment including the use of lokivetmab - caninized anti-interleukine-31 antibody. The aim of the study was to evaluate the effectiveness of lokivetmab over 12 weeks of treatment. Studies have been carried out in 89 dogs. In all affected animals, the severity of lesions was assessed using the CADESI 04 and the pruritus was assessed using the VAS. After the first dose of lokivetmab, both CADESI 04 and VAS statistical decreased by 4 weeks from 40.48 to 20.31, and from 7.42 to 2.48, respectively (p = 0.0000001) maintained significantly decresed values during the whole treatment period (CADESI 04 15.64, 15.07 after 8 and 12 weeks, respectively, PVAS 2.03, 1.95 after 8 and 12 weeks, respectively). Lokivetmab leads to a significant reduction of CADESI 04 and pruritus, within four weeks and maximum effect is achived after the second dose. L1 - http://journals.pan.pl/Content/116005/PDF/4.pdf L2 - http://journals.pan.pl/Content/116005 PY - 2020 IS - No 2 EP - 195 DO - 10.24425/pjvs.2020.132765 KW - atopic dermatitis KW - dog KW - lokivetmab A1 - Szczepanik, M.P. A1 - Popiel, J. A1 - Cekiera, A. A1 - Pomorska-Handwerker, D. A1 - Karaś-Tęcza, J. A1 - Ściskalska, M. A1 - Oczkowska, K. A1 - Taube, M. A1 - Olender, V. A1 - Parys, P. PB - Polish Academy of Sciences Committee of Veterinary Sciences PB - University of Warmia and Mazury in Olsztyn VL - vol. 23 DA - 2020.06.29 T1 - Evaluation of the clinical efficiencyof lokivetmab in client privately ownedatopic dogs – multicenter study SP - 191 UR - http://journals.pan.pl/dlibra/publication/edition/116005 T2 - Polish Journal of Veterinary Sciences ER -